aluates Reports

$ 0.0

Automative

Global siRNA Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-24S12503

Global siRNA Drugs Market Size Status and Forecast 2022 2028

BUY CHAPTERS

Global siRNA Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Code: QYRE-Auto-24S12503

Report

August 2025

Pages:80

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Alnylam

Sirnaomics

Novartis

Novo Nordisk

Genzyme

Arrowhead

Silence

Sylentis

Avidity Biosciences

siRNA Drugs Sales Market Size

The global siRNA Drugs market size was US$ 2443 million in 2024 and is forecast to a readjusted size of US$ 16238 million by 2031 with a CAGR of 28.9% during the forecast period 2025-2031.

siRNA Drugs Sales Market

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.

Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.

In-depth analysis of siRNA drug market driving factors

I. Technological breakthroughs: the leap from laboratory to clinic

Delivery system innovation

Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.

Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.

Mature chemical modification technology

Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.

Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.

2. Market demand: The outbreak of unmet clinical needs

Indications expand from rare diseases to common diseases

Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.

New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.

The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.

3. Policy support: Improvement of the global regulatory framework

China's policy dividends

"The 14th Five-Year Plan for the Development of the Pharmaceutical Industry": Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.

Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.

International regulatory coordination

FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.

EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.

IV. Capital influx: catalytic effect of industrial ecology

Increased investment and financing activity

Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).

MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.

CDMO service ecosystem matures

RiboBio, WuXi AppTec: Provide "one-stop" services from sequence design to cGMP production, reducing R&D costs by more than 50%.

Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.

V. Competitive landscape: From technical barriers to ecological barriers

Strengthening of patent layout

Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.

Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.

Cross-border cooperation is accelerating

Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.

Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.

VI. Challenges and coping strategies

Breakthrough in technical bottlenecks

Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.

Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.

Balance between cost and accessibility

Tiered pricing strategy: Adopt the "patent pool" model (such as MPP) in low-income countries to improve drug accessibility.

In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.

The global siRNA Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

Market Segmentation

Scope of siRNA Drugs Sales Market Report

Report Metric	Details
Report Name	siRNA Drugs Sales Market
Forecasted market size in 2031	US$ 16238 million
CAGR	28.9%
Forecasted years	2025 - 2031
By Type: (Dominant Segment vs High-Margin Innovation)	Intravenous Injection Subcutaneous Injection
By Application: (Core Demand Driver vs Emerging Opportunity)	Nervous System Therapy Endocrine and Metabolic Therapy Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company:	Alnylam, Novartis, Novo Nordisk, Genzyme, Arrowhead, Silence, Sylentis, Avidity Biosciences, Sirnaomics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of siRNA Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Subcutaneous Injection in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Endocrine and Metabolic Therapy in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the siRNA Drugs value chain, addressing:

FAQ for this report

What is the siRNA Drugs Sales Market size in 2031?

Ans: The siRNA Drugs Sales Market size in 2031 will be US$ 16238 million.

What is the siRNA Drugs Sales Market share by type?

Ans: In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%.

What is the siRNA Drugs Sales Market share by application?

Ans: In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.

Who are the main players in the siRNA Drugs Sales Market report?

Ans: The main players in the siRNA Drugs Sales Market are Alnylam, Novartis, Novo Nordisk, Genzyme, Arrowhead, Silence, Sylentis, Avidity Biosciences, Sirnaomics

What are the Application segmentation covered in the siRNA Drugs Sales Market report?

Ans: The Applications covered in the siRNA Drugs Sales Market report are Nervous System Therapy, Endocrine and Metabolic Therapy, Others

What are the Type segmentation covered in the siRNA Drugs Sales Market report?

Ans: The Types covered in the siRNA Drugs Sales Market report are Intravenous Injection, Subcutaneous Injection

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031

1.2.2 Intravenous Injection

1.2.3 Subcutaneous Injection

1.3 Market by Application

1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031

1.3.2 Nervous System Therapy

1.3.3 Endocrine and Metabolic Therapy

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global siRNA Drugs Market Perspective (2020-2031)

2.2 Global Market Size by Region: 2020 VS 2024 VS 2031

2.3 Global siRNA Drugs Revenue Market Share by Region (2020-2025)

2.4 Global siRNA Drugs Revenue Forecast by Region (2026-2031)

2.5 Major Region and Emerging Market Analysis

2.5.1 North America siRNA Drugs Market Size and Prospective (2020-2031)

2.5.2 Europe siRNA Drugs Market Size and Prospective (2020-2031)

2.5.3 Asia-Pacific siRNA Drugs Market Size and Prospective (2020-2031)

2.5.4 Latin America siRNA Drugs Market Size and Prospective (2020-2031)

2.5.5 Middle East & Africa siRNA Drugs Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

3.1 Global siRNA Drugs Historic Market Size by Type (2020-2025)

3.2 Global siRNA Drugs Forecasted Market Size by Type (2026-2031)

3.3 Different Types siRNA Drugs Representative Players

4 Breakdown Data by Application

4.1 Global siRNA Drugs Historic Market Size by Application (2020-2025)

4.2 Global siRNA Drugs Forecasted Market Size by Application (2026-2031)

4.3 New Sources of Growth in siRNA Drugs Application

5 Competition Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top siRNA Drugs Players by Revenue (2020-2025)

5.1.2 Global siRNA Drugs Revenue Market Share by Players (2020-2025)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by siRNA Drugs Revenue

5.4 Global siRNA Drugs Market Concentration Analysis

5.4.1 Global siRNA Drugs Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by siRNA Drugs Revenue in 2024

5.5 Global Key Players of siRNA Drugs Head office and Area Served

5.6 Global Key Players of siRNA Drugs, Product and Application

5.7 Global Key Players of siRNA Drugs, Date of Enter into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments and Downstream

6.1.1 North America siRNA Drugs Revenue by Company (2020-2025)

6.1.2 North America Market Size by Type

6.1.2.1 North America siRNA Drugs Market Size by Type (2020-2025)

6.1.2.2 North America siRNA Drugs Market Share by Type (2020-2025)

6.1.3 North America Market Size by Application

6.1.3.1 North America siRNA Drugs Market Size by Application (2020-2025)

6.1.3.2 North America siRNA Drugs Market Share by Application (2020-2025)

6.1.4 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments and Downstream

6.2.1 Europe siRNA Drugs Revenue by Company (2020-2025)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe siRNA Drugs Market Size by Type (2020-2025)

6.2.2.2 Europe siRNA Drugs Market Share by Type (2020-2025)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe siRNA Drugs Market Size by Application (2020-2025)

6.2.3.2 Europe siRNA Drugs Market Share by Application (2020-2025)

6.2.4 Europe Market Trend and Opportunities

6.3 Asia-Pacific Market: Players, Segments and Downstream

6.3.1 Asia-Pacific siRNA Drugs Revenue by Company (2020-2025)

6.3.2 Asia-Pacific Market Size by Type

6.3.2.1 Asia-Pacific siRNA Drugs Market Size by Type (2020-2025)

6.3.2.2 Asia-Pacific siRNA Drugs Market Share by Type (2020-2025)

6.3.3 Asia-Pacific Market Size by Application

6.3.3.1 Asia-Pacific siRNA Drugs Market Size by Application (2020-2025)

6.3.3.2 Asia-Pacific siRNA Drugs Market Share by Application (2020-2025)

6.3.4 Asia-Pacific Market Trend and Opportunities

6.4 Latin America Market: Players, Segments and Downstream

6.4.1 Latin America siRNA Drugs Revenue by Company (2020-2025)

6.4.2 Latin America Market Size by Type

6.4.2.1 Latin America siRNA Drugs Market Size by Type (2020-2025)

6.4.2.2 Latin America siRNA Drugs Market Share by Type (2020-2025)

6.4.3 Latin America Market Size by Application

6.4.3.1 Latin America siRNA Drugs Market Size by Application (2020-2025)

6.4.3.2 Latin America siRNA Drugs Market Share by Application (2020-2025)

6.4.4 Latin America Market Trend and Opportunities

6.5 Middle East & Africa Market: Players, Segments and Downstream

6.5.1 Middle East & Africa siRNA Drugs Revenue by Company (2020-2025)

6.5.2 Middle East & Africa Market Size by Type

6.5.2.1 Middle East & Africa siRNA Drugs Market Size by Type (2020-2025)

6.5.2.2 Middle East & Africa siRNA Drugs Market Share by Type (2020-2025)

6.5.3 Middle East & Africa Market Size by Application

6.5.3.1 Middle East & Africa siRNA Drugs Market Size by Application (2020-2025)

6.5.3.2 Middle East & Africa siRNA Drugs Market Share by Application (2020-2025)

6.5.4 Middle East & Africa Market Trend and Opportunities

7 Key Players Profiles

7.1 Alnylam

7.1.1 Alnylam Company Details

7.1.2 Alnylam Business Overview

7.1.3 Alnylam siRNA Drugs Introduction

7.1.4 Alnylam Revenue in siRNA Drugs Business (2020-2025)

7.1.5 Alnylam Recent Development

7.2 Novartis

7.2.1 Novartis Company Details

7.2.2 Novartis Business Overview

7.2.3 Novartis siRNA Drugs Introduction

7.2.4 Novartis Revenue in siRNA Drugs Business (2020-2025)

7.2.5 Novartis Recent Development

7.3 Novo Nordisk

7.3.1 Novo Nordisk Company Details

7.3.2 Novo Nordisk Business Overview

7.3.3 Novo Nordisk siRNA Drugs Introduction

7.3.4 Novo Nordisk Revenue in siRNA Drugs Business (2020-2025)

7.3.5 Novo Nordisk Recent Development

7.4 Genzyme

7.4.1 Genzyme Company Details

7.4.2 Genzyme Business Overview

7.4.3 Genzyme siRNA Drugs Introduction

7.4.4 Genzyme Revenue in siRNA Drugs Business (2020-2025)

7.4.5 Genzyme Recent Development

7.5 Arrowhead

7.5.1 Arrowhead Company Details

7.5.2 Arrowhead Business Overview

7.5.3 Arrowhead siRNA Drugs Introduction

7.5.4 Arrowhead Revenue in siRNA Drugs Business (2020-2025)

7.5.5 Arrowhead Recent Development

7.6 Silence

7.6.1 Silence Company Details

7.6.2 Silence Business Overview

7.6.3 Silence siRNA Drugs Introduction

7.6.4 Silence Revenue in siRNA Drugs Business (2020-2025)

7.6.5 Silence Recent Development

7.7 Sylentis

7.7.1 Sylentis Company Details

7.7.2 Sylentis Business Overview

7.7.3 Sylentis siRNA Drugs Introduction

7.7.4 Sylentis Revenue in siRNA Drugs Business (2020-2025)

7.7.5 Sylentis Recent Development

7.8 Avidity Biosciences

7.8.1 Avidity Biosciences Company Details

7.8.2 Avidity Biosciences Business Overview

7.8.3 Avidity Biosciences siRNA Drugs Introduction

7.8.4 Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025)

7.8.5 Avidity Biosciences Recent Development

7.9 Sirnaomics

7.9.1 Sirnaomics Company Details

7.9.2 Sirnaomics Business Overview

7.9.3 Sirnaomics siRNA Drugs Introduction

7.9.4 Sirnaomics Revenue in siRNA Drugs Business (2020-2025)

7.9.5 Sirnaomics Recent Development

8 siRNA Drugs Market Dynamics

8.1 siRNA Drugs Industry Trends

8.2 siRNA Drugs Market Drivers

8.3 siRNA Drugs Market Challenges

8.4 siRNA Drugs Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alnylam

Sirnaomics

Novartis

Novo Nordisk

Genzyme

Arrowhead

Silence

Sylentis

Avidity Biosciences

List of Tables

Table 1. Global siRNA Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global siRNA Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market siRNA Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global siRNA Drugs Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global siRNA Drugs Revenue Share by Region (2020-2025)

Table 6. Global siRNA Drugs Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global siRNA Drugs Revenue Share Forecast by Region (2026-2031)

Table 8. Global siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global siRNA Drugs Revenue Market Share by Type (2020-2025)

Table 10. Global siRNA Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global siRNA Drugs Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global siRNA Drugs Revenue Market Share by Application (2020-2025)

Table 15. Global siRNA Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global siRNA Drugs Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in siRNA Drugs Application

Table 18. Global siRNA Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global siRNA Drugs Market Share by Players (2020-2025)

Table 20. Global Top siRNA Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)

Table 21. Ranking of Global Top siRNA Drugs Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by siRNA Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of siRNA Drugs, Headquarters and Area Served

Table 24. Global Key Players of siRNA Drugs, Product and Application

Table 25. Global Key Players of siRNA Drugs, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America siRNA Drugs Revenue Market Share by Company (2020-2025)

Table 29. North America siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe siRNA Drugs Revenue Market Share by Company (2020-2025)

Table 33. Europe siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 35. Asia-Pacific siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 36. Asia-Pacific siRNA Drugs Revenue Market Share by Company (2020-2025)

Table 37. Asia-Pacific siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 38. Asia-Pacific siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 39. Latin America siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 40. Latin America siRNA Drugs Revenue Market Share by Company (2020-2025)

Table 41. Latin America siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 42. Latin America siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 43. Middle East & Africa siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 44. Middle East & Africa siRNA Drugs Revenue Market Share by Company (2020-2025)

Table 45. Middle East & Africa siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 46. Middle East & Africa siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 47. Alnylam Company Details

Table 48. Alnylam Business Overview

Table 49. Alnylam siRNA Drugs Product

Table 50. Alnylam Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 51. Alnylam Recent Development

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis siRNA Drugs Product

Table 55. Novartis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Novo Nordisk Company Details

Table 58. Novo Nordisk Business Overview

Table 59. Novo Nordisk siRNA Drugs Product

Table 60. Novo Nordisk Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 61. Novo Nordisk Recent Development

Table 62. Genzyme Company Details

Table 63. Genzyme Business Overview

Table 64. Genzyme siRNA Drugs Product

Table 65. Genzyme Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 66. Genzyme Recent Development

Table 67. Arrowhead Company Details

Table 68. Arrowhead Business Overview

Table 69. Arrowhead siRNA Drugs Product

Table 70. Arrowhead Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 71. Arrowhead Recent Development

Table 72. Silence Company Details

Table 73. Silence Business Overview

Table 74. Silence siRNA Drugs Product

Table 75. Silence Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 76. Silence Recent Development

Table 77. Sylentis Company Details

Table 78. Sylentis Business Overview

Table 79. Sylentis siRNA Drugs Product

Table 80. Sylentis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 81. Sylentis Recent Development

Table 82. Avidity Biosciences Company Details

Table 83. Avidity Biosciences Business Overview

Table 84. Avidity Biosciences siRNA Drugs Product

Table 85. Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 86. Avidity Biosciences Recent Development

Table 87. Sirnaomics Company Details

Table 88. Sirnaomics Business Overview

Table 89. Sirnaomics siRNA Drugs Product

Table 90. Sirnaomics Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)

Table 91. Sirnaomics Recent Development

Table 92. siRNA Drugs Market Trends

Table 93. siRNA Drugs Market Drivers

Table 94. siRNA Drugs Market Challenges

Table 95. siRNA Drugs Market Restraints

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List of Figures

Figure 1. siRNA Drugs Product Picture

Figure 2. Global siRNA Drugs Market Share by Type: 2024 VS 2031

Figure 3. Intravenous Injection Features

Figure 4. Subcutaneous Injection Features

Figure 5. Global siRNA Drugs Market Share by Application: 2024 VS 2031

Figure 6. Nervous System Therapy

Figure 7. Endocrine and Metabolic Therapy

Figure 8. Others

Figure 9. siRNA Drugs Report Years Considered

Figure 10. Global siRNA Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 11. Global siRNA Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global siRNA Drugs Revenue Market Share by Region: 2020 VS 2024

Figure 13. North America siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 14. Europe siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 15. Asia-Pacific siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. Latin America siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. Middle East & Africa siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Global siRNA Drugs Market Share by Players in 2024

Figure 19. Global Top siRNA Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by siRNA Drugs Revenue in 2024

Figure 21. North America siRNA Drugs Market Share by Type (2020-2025)

Figure 22. North America siRNA Drugs Market Share by Application (2020-2025)

Figure 23. Europe siRNA Drugs Market Share by Type (2020-2025)

Figure 24. Europe siRNA Drugs Market Share by Application (2020-2025)

Figure 25. Asia-Pacific siRNA Drugs Market Share by Type (2020-2025)

Figure 26. Asia-Pacific siRNA Drugs Market Share by Application (2020-2025)

Figure 27. Latin America siRNA Drugs Market Share by Type (2020-2025)

Figure 28. Latin America siRNA Drugs Market Share by Application (2020-2025)

Figure 29. Middle East & Africa siRNA Drugs Market Share by Type (2020-2025)

Figure 30. Middle East & Africa siRNA Drugs Market Share by Application (2020-2025)

Figure 31. Alnylam Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 32. Novartis Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 33. Novo Nordisk Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 34. Genzyme Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 35. Arrowhead Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 36. Silence Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 37. Sylentis Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 38. Avidity Biosciences Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 39. Sirnaomics Revenue Growth Rate in siRNA Drugs Business (2020-2025)

Figure 40. Bottom-up and Top-down Approaches for This Report

Figure 41. Data Triangulation

Figure 42. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4250

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$6375

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$8500

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Antisense and RNA Interference Therapeutics Market Research Report 2024

Global RNA Interference RNAi Drug Delivery Market Research Report 2025

Global RNA Targeted Small Molecule Drugs Market Research Report 2025

RNA Based Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Nucleic Acid based Drugs Market Research Report 2024

Global siRNA Drug Market Research Report 2024

Small Molecule Nucleic Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Diagnostic Guidewire Market Research Report 2024

Global Still s Disease Treatment Market Research Report 2025

Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024

Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Nano Pharmaceutical Market Research Report 2024

Global Drug Safety and Pharmacovigilance Service Market Research Report 2025

Global Drugs of Abuse Testing Market Research Report 2024

Global Pharmaceutical Validation Services Market Research Report 2025

Global Treatment Planning Software Market Research Report 2025

Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024

Global Combination Therapy Drug Market Research Report 2025

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions